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Using an Electronic Health Record Alert System to Screen and Manage Patients with Diabetes Mellitus 
Type 2 in a Rural Primary Care Setting 
Simon Katumu 
Introduction  
The Centers for Disease Control and Prevention (CDC) estimates that about 30.3 million adult 
Americans had diabetes in 2015 and this number is rising. It is estimated that one in four people living 
Diabetes Mellitus type 2 (DM2) are not aware of their diagnosis and therefore not under any form of 
treatment (CDC, 2015). DM2 causes significant morbidity and mortality. It was the 7th leading cause of 
death in 2015 as the primary cause of death in 79,535 people and the secondary cause in 252,806 
people.(CDC, 2017). Uncontrolled DM2 results in increased micro and macrovascular complications 
including retinopathy, neuropathy, nephropathy, metabolic syndrome and atherosclerosis. (Brinkhues & 
Dukers-Muijrers et al. 2018). Retinopathy risk is 61.7% higher in patients with uncontrolled DM2 for at 
least 10 years and the risk for cardiopathy was increased by 69.0%.   
The American Association of Diabetes (ADA) advocates for routine screening with the 
hemoglobin A1C (HgbA1C) test for early detection and management of DM2 (ADA 2017). The United 
States preventative services taskforce (USPTF) also recommends DM2 screening for all adults over the 
age of 40 who are considered overweight or obese (2017). Screening for DM2 should start early in those 
with multiple risk factors starting at 21 years of age or younger in cases of extreme obesity and should 
be repeated either yearly or every 3 years depending on the number and/or severity of risk factors. 
Once diagnosis has been made, hemoglobin A1C (hgbA1C) levels should be checked every 3 months for 
those who haven’t met their treatment goals and every year for those who have met their treatment 
goals. (Qaseem, Wilt, Kansagara et al., 2018).   
This project was designed to increase the rate of screening for at-risk patients and the frequency 
of testing for those already diagnosed. The setting was a rural primary care clinic in a federally classified 
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underserved community with a large population of patients with DM2. Screening at risk patients and re-
testing diagnosed patients were major problems at this clinic. An alert system to notify providers when 
patients were due for hbgA1C testing did not exist.  New patients at high risk of DM2 were not being 
screened routinely and existing patients with DM2 would come for office visits without getting routine 
hgbA1C testing. Many patients with DM2 were found to have lapses of several months or years without 
having hbgA1C monitoring.     
Literature Review  
The ADA recommends screening all adults over the age of 45 at least once every year and all 
younger patients with major risk factors annually. The following are key risk factors for DM 2; family 
history especially in a parent or sibling, obesity with a BMI greater than 27 kg/m2 or 20% over desired 
body weight, African American, Hispanic American, Native American, Asian-American or Pacific Islander 
racial or ethnic background, age over 45, prior history of impaired fasting glucose or impaired glucose 
test, hyperlipidemia, hypertension and history of gestational diabetes or delivery of a baby weighing 
over 9 lbs. Pippitt and Gurgle (2016) state that all patients with risk factors should be screened routinely 
at least every 2 years but if new risk factors such as weight gain occur, then they should be re-screened 
as soon as those risk factors are noticed. The USPTF also recommends screening all adults aged 40 to 70 
who are overweight or obese at least every 3 years. Patients who have more than one risk factor 
regardless of age should be screened earlier and more frequently.  
Arrendale, Cherian & Zineh et al. (2008) found that for best outcomes, patients with DM2 
should have their hgbA1Cs tested every 3 months for better management and glycemic control. 
Shahraz, Pittas & Saadati et al. (2017) also show that frequent testing of hgbA1C levels  led to better 
outcomes overall for patients with DM2. Qaseem, Wilt & Kansagara et al. (2018) state that the 
recommended hgbA1C goal of treatment in most patients with DM2 is between 7% and 8%. The 
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recommended goal is lower than 7% in younger and 8% or higher in older patients or those with life 
expectancies less than 10 years due to an advanced disease process.   
Mann and Lin (2012) developed a clinical tool embedded into EHR systems that significantly 
increased the communication between healthcare providers and their patients leading to better 
outcomes.  Wright et al. (2012) found that patients who used an electronic reminder system for routine 
screening tests had significantly better outcomes than those who did not receive reminders.  
Project Methods  
The goals of this project were to increase hgbA1C screening rates by alerting providers when 
they saw patients who were at risk of developing DM2 and to increase hgbA1C monitoring at 
appropriate intervals in patients with existing disease. This project implemented the use of a tool in the 
clinic’s electronic health record system called ‘clinical guidelines’. This tool utilizes data that is entered 
into a patient’s chart to determine the specific needs of every patient. For example, if a patient’s 
hgbA1C is noted to be over 7%, then 3 months later, the tool will show that he/she is due for a recheck 
until a new number is captured. The tool captures data such as a patient’s BMI, Family history of 
diabetes, current or past hgbA1C readings, glucose test results and diagnoses such as obesity, 
neuropathy and cardiopathy. The project required the accurate input of all relevant clinical data as well 
as the careful monitoring of the clinical guidelines icon by the providers during every visit to determine 
when and if any testing was necessary or due. The use of the clinical guideline tool went live on 
September 3rd, 2018. A proposal to conduct research involving human subjects was submitted and 
reviewed by the Institutional Review Board (IRB) at Southern Illinois University Edwardsville and found 
to be exempt from IRB review.  
Evaluation  
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Clinical data was collected on all patients at the clinic with elevated hgbA1Cs greater than 5.7% 
mg/dL from May 2018 to November 2018. The data collected from May - July showed numbers prior to 
the implementation of the project. Data collected from September - November showed numbers after 
the implementation of the tool into the EHR. No data was collected for the month of August 2018 to 
avoid any overlap of pre and post implementation numbers. Prior to project implementation, a total of 
66 hgbA1Cs were noted to be above 5.7% and 30 of them were 7% and above. Of the 66 readings, 17 
(25.8%) were on patients who had not been diagnosed with DM2 previously and 49 were on already 
diagnosed patients. After implementation, the total number of hgbA1C readings noted to be above 5.7% 
was 71 with 25 of them being over 7%. This time the number of previously undiagnosed cases was 21 
(29.6%) while the number of already diagnosed cases was 50.  
There was an increase in the total number of cases tested for hgbA1C improving from 66 to 71 
within a similar time frame. The number of cases with hgbA1C readings over 7% decreased from 30 to 
25 and the number of newly identified cases also went up from 17 (25.8%) to 21 (29.6%) . These 
numbers were obtained with the help of the clinic’s quality assurance department, which collects and 
reviews this data. The increase in the number of cases tested for hgbA1C is an indication that the clinical 
guidelines tool did prompt providers to order more tests which led to improved numbers because higher 
readings have to be addressed by the providers.   
Providers reported that time constraints prohibited them from being able to implement the tool 
or they either forgot to click on the clinical guidelines icon to determine if a patient was deemed to be at 
risk for DM2 or was due or overdue for hgbA1C testing or deferred that task to the next visit. For this 
reason, it is likely that several cases still went undetected. A closer review of patients’ reports showed 
that even after the implementation of the project, there was still a large number of patients who were 
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supposed to return for retesting in 3 months but didn’t do so. A recommendation for follow up calls was 
made but a good number of them were unreachable.  
Impact on practice  
The initial reaction by most of the clinic staff at the introduction of the project was excitement 
and enthusiasm but the implementation phase proved to be more challenging and the initial enthusiasm 
was overshadowed by feelings of frustration at the new changes. Many staff members reported that 
finding the alert added time to the patient visit. This led to some resistance especially since this was not 
something that was required by company policy. However, over time participation and morale 
increased. Providers began to ‘catch’ cases that would have otherwise gone unnoticed which 
encouraged and motivated them to use the tool more. By the end of project implementation period, 
many providers had made the tool an everyday component of their practice and planned to use it long-
term.  
The tool that was implemented in this project is not what was initially planned. The initial plan 
was for an ‘alert’ system that would not require clicking an icon but would automatically pop-up 
whenever a patient met the criteria to notify the provider that the patient needed to be screened or 
retested for DM2. However, when the IT department and the EHR software developer were notified of 
the planned project, the quoted price was higher than expected and the organization could not make 
the investment at the time. The use of the clinical guideline tool was thought of as a way of 
accomplishing the same goal without the alert system. Acquiring the actual alert system would be more 
effective and time saving for the clinic leading to better patient outcomes.  
Conclusion  
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The implementation of this project was instrumental in identifying new cases of DM2 by 
increasing the rate of screenings for at-risk patients leading to the initiation of treatment and avoidance 
of possible complications. The reminder system also increased the frequency of monitoring for 
diagnosed patients every 3 months leading to better management of their medications and better 
glycemic control. It is recommended that an additional reminder system be implemented to alert staff 
members when patients are due or overdue for hgbA1C testing and prompt them to make reminder 
calls to these patients to come in for re-testing.   
The project outcomes demonstrate that the reminder system met its goals by increasing the 
overall number of hgbA1Cs checked, the number of new cases diagnosed and the rate of re-testing for 
diagnosed patients. Although these goals were met, not all potential cases were diagnosed and some 
patients still missed their three-month testing after the project implementation. Therefore, it is 
recommended that the system be made easily accessible and visible for the providers. When providers 
have to navigate away from the primary screen on the computer to access it, the extra click decreases 
their likelihood of using it. The elimination of this click is likely to lead to more compliance by providers. 
Another recommendation is for an expansion of the use of this tool to other community healthcare 
settings since this is not an isolated issue and its widespread use is likely to lead to more diagnoses and 
better care and outcomes for patients.  
There are numerous tasks and obligations to be completed during office visits but remembering 
to do something as simple as ordering a blood test could mean the difference between a life-changing 
diagnosis and a missed opportunity to change a life forever. In today’s fast-paced world, small measures 
such as this simple reminder can go a long way in ensuring that patients with DM2 live long healthy 
lives.   
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